[Antimutagenic hypoxen activity in vivo].
The antimutagen effect of the drug hypoxen, representing poly(2,5-dihydroxyphenylene)-4-thiosulfonic acid sodium salt, was studied by chromosome aberration assay in the bone marrow cells of C57BL/6 mice. Hypoxen (20 mg/kg, i.p.) administered simultaneously with dioxidine (300 mg/kg, i.p.) reduced genotoxicity of the latter compound by 35% over a time period of 24 h. Preliminary five-day administration of hypoxen (70 mg/kg, p.o.) did not decrease the dioxidine damage. The genoprotector activity of hypoxen upon interaperitoneal injection is more pronounced as compared to that of the reference drug sladex (aspartam).
Karpova
O A
OA
Molecular Genetics and Immunology Department, Research Center for Toxicological and Hygienic Control of Biopreparations, ul. Lenina 102A, Serpukhov, Moscow Oblast, 142253 Russia.
Mikhina
L V
LV
Denisov
A A
AA
Kuz'mich
M K
MK
D000818:Animals; D016587:Antimutagenic Agents / Q000494:pharmacology*; D001854:Bone Marrow Cells / Q000187:drug effects / Q000473:pathology; D002869:Chromosome Aberrations / Q000187:drug effects; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009152:Mutagenicity Tests; D009153:Mutagens / Q000633:toxicity; D011108:Polymers; D011810:Quinoxalines / Q000633:toxicity; D012118:Resorcinols / Q000494:pharmacology*; D013451:Sulfonic Acids / Q000494:pharmacology*
D016587:Antimutagenic Agents; D009153:Mutagens; D011108:Polymers; D011810:Quinoxalines; D012118:Resorcinols; D013451:Sulfonic Acids; C001077:dioxidine